Renal safety profile of sodium-glucose cotransporter-2 inhibitors and other safety data. / Perfil de seguridad renal de los inhibidores del cotransportador sodio-glucosa tipo 2 y otros datos de seguridad.

The main effect of SGLT2 inhibitors is their glycosuric action. These drugs reverse the deleterious effect of increased glucose reabsorption by the renal tubule in persons with DM2. In terms of efficacy, SGLT2 inhibitors produce a mean HbA1c reduction of 0.8%, although higher initial HbA1c levels can show a larger decrease. In addition to these glycaemic effects, this drug class also favours weight loss and blood pressure control, without increasing hypoglycaemic episodes. Due to their insulin-independent mechanism of action, SGLT2 inhibitors can be used in monotherapy, in patients with metformin intolerance, or in combination with other glucose-lowering drugs, including insulin. These drugs have few secondary effects and most are related to their mechanism of action. The most frequent adverse effects are genitourinary infections, usually mycotic infections. SGLT2 inhibitors have an adequate cardiovascular safety profile. The development of ketoacidosis remains to be elucidated, and may be related to use in patients with insulinopenia. A randomised clinical trial of an SGLT2 inhibitor in patients with DM2 and underlying cardiovascular disease showed that its use in association with standard therapy slowed the progression of renal damage and reduced significant renal events such as doubling of serum creatinine values and initiation of dialysis. These effects are probably due to the favourable effects of SGLT2 inhibition on glomerular haemodynamics, by reducing hyperfiltration, to the reduction of glucose-induced tubular toxicity, as well as its beneficial effects on glycaemia, blood pressure, weight, and uricaemia.